N/A N=93 Randomized Diagnostic

Rapid Flu Tests in Travelers With Fever

Influenza

Bottom Line

View on ClinicalTrials.gov: NCT00821626 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2020

Primary outcome: Primary: Cost for the Medical Management of Patients — 581; 661 USD

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: BD Directigen EZ Flu A+B (Device); Control (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Lausanne Hospitals
Primary completion: May 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Cost for the Medical Management of Patients	581; 661	—
SECONDARY Chest X-ray Requested	9; 2	—
SECONDARY Number of Patients Receiving a Prescription for Antibiotics	14; 13	—

Summary

Influenza is a frequent cause of fever in returning travelers. Usually diagnosis rests on the clinical picture. Rapid flu tests are becoming increasingly popular, although their sensitivity and specificity are suboptimal. The objective of this study is to evaluate if rapid flu tests influence the medical management of returning travelers with fever, a population at intermediate risk for influenza infections.

Eligibility Criteria

Inclusion Criteria

Adults 18 years or older
Returning from abroad within the last 14 days
Documented fever of 38oC or above or anamnestic fever + cough or sore throat within the last 4 days before the consultation.

Exclusion Criteria

Unwillingness to participate

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00821626). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.